Clinical Trials List
2019-05-19 - 2027-01-25
Phase III
Recruiting4
ICD-10C67.0
Malignant neoplasm of trigone of bladder
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9188.0
Malignant neoplasm of trigone of urinary bladder
-
Trial Applicant
BRISTOL-MYERS SQUIBB (TAIWAN) LTD.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/01
Investigators and Locations
Co-Principal Investigator
- Yi-Hsiu Huang Division of Urology
- Mu-Hsin Chang Division of Urology
- Chih-Chieh Lin Division of Urology
- Tzu-chun Wei Division of Urology
- 沈書慧 Division of Urology
- Yen-Hwa Chang Division of Urology
- Chueh-Chuan Yen Division of Urology
- Jiun-I Lai Division of Urology
- Hsiao-Jen Chung Division of Urology
- 潘競成 Division of Urology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- CHUNG-HSIN CHEN Division of Hematology & Oncology
- JHE-CYUAN GUO Division of Hematology & Oncology
- - - Division of Hematology & Oncology
- 洪士鈞 Division of Hematology & Oncology
- - - Division of Hematology & Oncology
- Chia-Chi Lin Division of Hematology & Oncology
- Yeong-Shiau Pu Division of Hematology & Oncology
- YU-CHUAN LU Division of Hematology & Oncology
- Ying-Chun Shen Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Shian-Shiang Wang Division of Urology
- Chia-Yen Lin Division of Urology
- 熊小澐 Division of Radiology
- Cheng-Kuang Yang Division of Urology
- 王樹吉 Division of Urology
- Cheng-Che Chen Division of Urology
- 廖博崎 Division of Urology
- 裘坤元 Division of Urology
- 盧嘉文 Division of Urology
- 洪啟峰 Division of Urology
- 賴谷順 Division of Urology
- Chuan-Shu Chen Division of Urology
- 洪晟鈞 Division of Urology
- Jian-Ri Li Division of Urology
- JU-CHUAN HU Division of Urology
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
21 participants
-
Global
1200 participants